ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print July 26, 2006, 10.1183/09031936.06.00126005
Eur Respir J 2006; 28:772-780
Copyright ©ERS Journals Ltd 2006
doi: 10.1183/09031936.06.00126005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/4/772    most recent
09031936.06.00126005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, S.
Right arrow Articles by Reiss, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, S.
Right arrow Articles by Reiss, T. F.

An oral selective M3 cholinergic receptor antagonist in COPD

S. Lu1, D. D. Parekh1, O. Kuznetsova2, S. A. Green1, C. A. Tozzi1 and T. F. Reiss1

1 Depts of Respiratory and Allergy, and 2 Biostatistics, Merck Research Laboratories, Rahway, NJ, USA.

CORRESPONDENCE: T. F. Reiss, Merck Research Laboratories, RY 34B-328, P.O. Box 2000, Rahway, NJ 07065, USA. Fax: 1 7325947830. E-mail: theodore_reiss{at}merck.com

Keywords: Anticholinergics, antimuscarinic agents, bronchodilators, chronic obstructive pulmonary disease, ipratropium bromide, muscarinic receptors

Received: October 28, 2005
Accepted June 26, 2006

Cholinergic antagonists have been used since the early 1900s as bronchodilators for chronic obstructive pulmonary disease (COPD). The present study investigated whether an oral muscarinic M3-selective anticholinergic agent (OrM3) would provide an improved therapeutic advantage compared with an inhaled anticholinergic agent in patients with COPD.

A 6-week, multicentre, randomised, placebo- and active-controlled, parallel-group study was performed at 56 sites in the USA. In total, 412 male and female patients (aged 35–86 yrs) with a clinical history consistent with COPD were randomised to receive OrM3 0.5, 2, 3 or 4 mg orally once daily, ipratropium bromide 36 µg by inhalation four times daily or placebo.

OrM3 demonstrated a significant dose-related improvement in serial forced expiratory volume in one second and a trend for dose-related improvement in patient-reported symptoms compared with placebo. However, at a dose that provided efficacy less than that of ipratropium, the incidence of dose-related, mechanism-based side-effects for OrM3 exceeded those observed for ipratropium.

In patients with chronic obstructive pulmonary disease, the oral M3-selective agent did not offer a therapeutic advantage over inhaled ipratropium. These results do not support the hypothesis that high selectivity for muscarinic M3 receptors over airway neuronal M2 receptors will represent a more effective therapy than current inhaled anticholinergics in obstructive airway disease.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
R. Gosens, D. Rieks, H. Meurs, D. K. Ninaber, K. F. Rabe, J. Nanninga, S. Kolahian, A. J. Halayko, P. S. Hiemstra, and S. Zuyderduyn
Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells
Eur. Respir. J., December 1, 2009; 34(6): 1436 - 1443.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.